Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ: RIGL · Real-Time Price · USD

45.71

-5.58 (-10.88%)

At close: Nov 5, 2026, 4:00 PM EST

41.74

-3.97 (-8.69%)

Pre-market: Nov 6, 2026, 4:24 AM EST

Rigel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	46.65	40.58	56.75	32.79	24.46	18.89
Short-Term Investments	52.66	114.38	20.58	24.15	33.75	106.08
Cash & Short-Term Investments	99.31	154.96	77.32	56.93	58.21	124.97
Cash Growth	-27.59%	100.41%	35.81%	-2.19%	-53.42%	117.99%
Receivables	56.46	51.76	41.62	30.55	40.32	15.47
Inventory	15.81	23.36	9.76	5.52	17.38	6.62
Prepaid Expenses	16.96	4.89	1.89	6.26	-	7.41
Other Current Assets	-	5.21	4.52	-	-	-
Total Current Assets	188.52	240.17	135.1	99.27	115.9	154.47
Property, Plant & Equipment	0.5	0.95	0.34	1.03	2.79	11.89
Other Intangible Assets	94.59	24.75	27.1	13.88	14.95	-
Long-Term Deferred Tax Assets	234.53	245.85	-	-	-	-
Other Long-Term Assets	5.74	1.88	1.44	3.06	0.64	0.97
Total Assets	523.88	513.59	163.98	117.23	134.28	167.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	11.44	7.19	3.34	7.14	22.51	3.8
Accrued Expenses	32.73	50.46	46.33	29.28	31.91	31.75
Current Portion of Long-Term Debt	7.24	29.81	7.27	10.87	3.94	7.97
Current Portion of Leases	0.56	0.61	0.29	0.69	1.13	9.89
Current Unearned Revenue	-	1.36	1.36	1.36	1.37	2.6
Other Current Liabilities	26.81	9.81	4.72	3.93	4.36	7.55
Total Current Liabilities	78.77	99.24	63.3	53.27	65.21	63.55
Long-Term Debt	-	22.48	92.39	92.32	81.71	72.64
Long-Term Leases	-	0.4	-	0.29	0.97	0.76
Other Long-Term Liabilities	-	-	5	-	-	-
Total Liabilities	78.77	122.11	160.69	145.87	147.9	136.95

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.17	0.17
Additional Paid-In Capital	1,429	1,414	1,393	1,379	1,369	1,354
Retained Earnings	-983.91	-1,023	-1,390	-1,408	-1,382	-1,324
Comprehensive Income & Other	-0.31	0.18	0.01	0.01	-0.15	-0.1
Shareholders' Equity	445.11	391.48	3.29	-28.64	-13.62	30.37
Total Liabilities & Equity	523.88	513.59	163.98	117.23	134.28	167.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	7.79	53.3	99.95	104.17	87.75	91.27
Net Cash (Debt)	91.51	101.65	-22.63	-47.23	-29.55	33.7
Net Cash Growth	20.00%	-	-	-	-	84.77%
Net Cash Per Share	4.58	5.40	-1.28	-2.71	-1.73	1.98
Filing Date Shares Outstanding	18.83	18.47	17.86	17.54	17.37	17.17
Total Common Shares Outstanding	18.83	18.31	17.71	17.48	17.34	17.16
Working Capital	109.75	140.93	71.8	46	50.69	90.91
Book Value Per Share	23.64	21.38	0.19	-1.64	-0.79	1.77
Tangible Book Value	350.52	366.73	-23.81	-42.52	-28.57	30.37
Tangible Book Value Per Share	18.62	20.03	-1.34	-2.43	-1.65	1.77
Machinery	-	-	-	1.83	9.48	16.04
Construction In Progress	-	-	-	-	-	0.69
Leasehold Improvements	-	-	-	-	2.11	-

SEC Filings: 10-K · 10-Q